Optimapharm
ActiveSummary
Optimapharm has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €96,701 and a net result of €92,091. Equity is growing by about 61% per year across the filed financial years. Its solvency ranks better than 33% of 3,019 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- OPTIMAPHARM
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaams Gewest, bij enkel besluit bestuursorgaan, administratieve zetels, agentschappen, werkhuizen, stapelplaatsen en bijkantoren in België…” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Één of meer bestuurders, natuurlijke personen of rechtspersonen, al dan niet aandeelhouder” (deed in Dutch)
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Vormen statutenwijziging, algemene vergadering” (deed in Dutch)
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Om welke reden en op welk ogenblik ook, geen andere vereffenaar benoemd” (deed in Dutch)